Elinogrel (PRT060128) 是一种有效的、直接作用的、竞争性的、可逆的血小板 P2Y12 拮抗剂 (IC50=20 nM)。
| Cas No. | 936500-94-6 |
| 别名 | 5-氯-N-[[[4-[6-氟-1,4-二氢-7-(甲基氨基)-2,4-二氧代-3(2H)-喹唑啉基]苯基]氨基]羰基]-2-噻吩磺酰胺,PRT060128 |
| 化学名 | 5-chloro-N-[[[4-[6-fluoro-1,4-dihydro-7-(methylamino)-2,4-dioxo-3(2H)-quinazolinyl]phenyl]amino]carbonyl]-2-thiophenesulfonamide |
| Canonical SMILES | CNC1=C(F)C=C(C(N(C2=CC=C(NC(NS(C3=CC=C(Cl)S3)(=O)=O)=O)C=C2)C(N4)=O)=O)C4=C1 |
| 分子式 | C20H15ClFN5O5S2 |
| 分子量 | 523.9 |
| 溶解度 | DMSO: 100 mM |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Elinogrel (PRT060128) is a potent, direct acting, competitive, and reversible platelet P2Y12 antagonist (IC50=20 nM). It is orally and intravenously available and has potent antiplatelet effects[1]. References:
[1]. Angiolillo DJ, et al. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudyfrom the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. Circ Cardiovasc Interv. 2012 Jun;5(3):347-56.
[2]. Jacobson KA, et al. Pharmacochemistry of the platelet purinergic receptors. Purinergic Signal. 2011 Sep;7(3):305-24. |
